Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis

Atopic Dermatitis Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site Clinical Study to Evaluate the Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Moderate to Severe Atopic Dermatitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00833079
• Other study ID #: TACR-0707
• Status: Completed
• Phase: Phase 1
• First received: January 28, 2009
• Last updated: January 19, 2014
• Start date: October 2008
• Est. completion date: March 2010

Study information

• Verified date: January 2014
• Source: Taro Pharmaceuticals USA
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc. and Protopic® (tacrolimus), 0.1% topical ointment (Astellas Pharma US, Inc.) and to show superiority over vehicle in the treatment of moderate to severe atopic dermatitis.

The secondary objectives are to compare the adverse event (AE) profiles of the two ointments and to investigate their systemic absorption at steady state.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: March 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or non-pregnant, non-lactating female, 18 years of age or older.

• Patient has documented evidence that they have been unresponsive to alternative more traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.

• If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives).

• Have confirmed diagnosis of atopic dermatitis using the diagnostic features as described by Hanifin and Rajka.

• Have an IGSA score of 3 (moderate) or 4 (severe)

• Have an affected Body Surface Area (BSA) of at least 20%

• Have a minimum Eczema Area and Severity Index (EASI) score of at least 15

Exclusion Criteria:

• Mild atopic dermatitis as defined by IGSA score of 0 (clear), 1 (almost clear), or 2 (mild) OR %BSA affected less than 20% OR EASI Score of less than 15.

• Clinically infected atopic dermatitis at the baseline visit. Tacrolimus is not indicated for the treatment of clinically infected atopic dermatitis

• Any dermatological condition other than atopic dermatitis that in the Investigator's opinion may interfere with the evaluation of the patient's atopic dermatitis

• Females who are pregnant, lactating or likely to become pregnant during the study.

• History of allergy or sensitivity to tacrolimus, pimecrolimus, any macrolides such as clindamycin erythromycin

• Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressants, including but not limited to human immunodeficiency virus (HIV) and cancer.

• Use of any nonsteroidal immunosuppressants

• Regular use of intranasal or inhaled corticosteroids, greater than the equivalent of 2 mg of prednisone/day, within 14 days of the first dosing day.

• Use of non-sedating histamines are not allowed for at least 7 days prior to the first dosing day or throughout the study.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Atopic Dermatitis
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• Tacrolimus 0.1% manufactured by Taro
Treatment applied as a thin layer to target area twice daily for 14 days
• Protopic - Tacrolimus 0.1%
Treatment applied as a thin layer to target area twice daily for 14 days
• Tacrolimus Vehicle manufactured by Taro
Treatment applied as a thin layer to target area twice daily for 14 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Taro Pharmaceuticals USA

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ISGA score 0 or 1		14 days	No
Secondary	% change in BSA		14 days	No
Secondary	% change in EASI		14 days	No
Secondary	% change in ISGA		14 days	No
Secondary	Safety and adverse event profile		14 days	Yes